BioScience Managers Limited
VC Fund
Melbourne, Australia
BioScience Managers Limited is a VC fund in Melbourne focused on Health Care and Biotechnology. BioScience Managers Pty Ltd (formerly IB Managers) is a leading life sciences investment firm, headquartered in Melbourne, Australia. Established in 2003, BioScience Managers offers a global, multi-disciplinary team, bringing an international perspective together with the track record, networks and expertise required to convert that perspectiveinto informed, high return investment decisions.We operate a high value-add model, providing assistance and support to portfolio companies via our global team and international network of independent industry advisors. With combined experience of over 170 investments, more than 40 IPO’s/ reversals in Europe, the USA and Australia, and a diverse skillset specific to the bio-based industries, we aim to provide investee companies with significant value-add over and above capital invested.Alongside our funds management business, Phillip Bioscience Advisory provides specialist corporate advisory services to healthcare and life sciences companies.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 22%
Last updated:
For AI agents: llms.txt
Industries BioScience Managers Limited invests in
Stages BioScience Managers Limited invests in
Countries BioScience Managers Limited invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 8 contacts → | |||
Investment Focus
Industry
- Health Care 5 (56%)
- Biotechnology 5 (56%)
- Medical 2 (22%)
- Life Science 2 (22%)
- Medical Device 2 (22%)
Stage
- Funding Round 3 (33%)
- Post-IPO Equity 3 (33%)
- Private Equity 2 (22%)
Country
- Australia 4 (44%)
- United States 2 (22%)
- Canada 1 (11%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Amanda Gillon
Investment Analyst
|
Investment Analyst | Total investments: 1 | Find email | |
Matt McNamara
Managing Director
|
Managing Director | Total investments: 4 | Find email | |
Nora Frey
Investment Manager
|
Investment Manager | Total investments: 2 | Find email | |
Bronwyn Dilley
senior executive
|
senior executive | Total investments: 0 | Find email | |
Jeremy Curnock Cook
Manager
|
Manager | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| We are a North American company, whose mission is to provide high quality medications for those patients who need them to treat their disease by making the medicine accessible to everyone. Our reason for being is to close the gap between pharmaceutical manufacturers and patients around the world whose quality of life depends on receiving the righttreatment at the right place and time.At Pharmaxis Group we believe that working closely with our customers, employees, shareholders and key partners allows us to provide exceptional value in all the services we provide. Specialized in the supply of drugs that are difficult to find in the fields of oncological, immunological, orphan diseases among others.Our global network of pharmaceutical suppliers, combined with our strong logistics network, includes certified partners in good storage and handling practices, and good manufacturing practices, all necessary to properly guarantee high quality in all the products and services. | Private Equity / Jan 01, 2022 | ||
| Immunosis is a biotech company developing innovative genetic technologies for the early detection of Primary Immune Deficiency | Private Equity / Jan 01, 2021 | ||
| Acrux is a specialty pharmaceutical company, developing and commercialising a range of patented, patient-preferred healthcare products for global markets, using its innovative technology to administer drugs through the skin.Acrux's product pipeline includes treatments of hormonal deficiencies, pain, central nervous system disorders and acontraceptive. 20 human clinical trials have been completed with 8 different drugs and the lead product, Evamist(TM), is nearing the end of a phase 3 trial in the USA. | $7.8M / Post-IPO Equity / Dec 21, 2020 | ||
| Cynata Therapeutics Limited is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, using discoveries made at the University of Wisconsin-Madison (UWM). UWM is a world-renowned leader in stem cell research, in particular for the work by Professor James Thomson'sgroup, which included the first successful isolation of human embryonic stem cells in 1998, and the derivation of induced pluripotent stem cells (iPSCs) from human adult cells in 2007. Professor Igor Slukvin, a co-founder of Cynata, was also a member of the team that conducted UWM's pioneering iPSC research.Cynata's Cymerus™ platform stem cell technology is based upon extremely important and versatile stem cells known as mesenchymoangioblasts (MCAs). MCAs are a precursor of mesenchymal stem (or stromal) cells (MSCs) which are at the forefront of a new generation of treatments being investigated for such devastating diseases as osteoarthritis, Crohn’s disease and heart disease. Cynata’s proprietary technology utilizes iPSCs originating from an adult donor as the starting material for generating MCAs and in turn for manufacturing the MSC therapeutic product.Cynata will use the proprietary Cymerus™ technology to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. This opens up a wide range of therapeutic and manufacturing possibilities for the Company.The Cymerus™ technology has several characteristics which makes it ideal for the development of cell-based therapeutics. Most critically, the Cymerus™ manufacturing process ensures that cells for therapeutic use can be produced in virtually limitless quantities. This means that Cynata will not have to constantly seek out fresh stem cell donors to fuel its manufacturing demands. This has the potential to create a new standard in the emergent arena of regenerative medicine and stem cell therapeutics and provides Cynata with both a unique differentiator and an important competitive position. | $15M / Post-IPO Equity / Dec 11, 2020 | ||
| Adherium (previously known as Nexus6) is a privately owned developer and manufacturer of solutions that help patients and their healthcare professionals monitor and increase patient adherence to prescribed therapies, leading to improved disease management and reduced healthcare costs. | $3.3M / Post-IPO Equity / May 26, 2020 | ||
| BioScience Managers Commits AUS$10M to New joint venture with Canary medical to serve as a platform to collect and monetize data from implantable and wearable medical devices.Vancouver, British Columbia, Aug 1, 2017 – Canary Medical (Canary) is pleased to announce the formation of CHARM Informatics Pty Ltd (CHARM), in collaboration with BioScienceManagers Pty Ltd (BioScience) of Melbourne, Australia. | May 18, 2018 | ||
| BioScience Managers Commits AUS$10M to New joint venture with Canary medical to serve as a platform to collect and monetize data from implantable and wearable medical devices.Vancouver, British Columbia, Aug 1, 2017 – Canary Medical (Canary) is pleased to announce the formation of CHARM Informatics Pty Ltd (CHARM), in collaboration with BioScienceManagers Pty Ltd (BioScience) of Melbourne, Australia. | $10M / May 17, 2018 | ||
| Our mission is to be a revolutionary force in the growing US$25 billion global animal pharmaceutical market. Only Nexvet can produce therapeutic antibodies that are 100% customised to target new species – like cats and dogs.Monoclonal antibody therapies have represented a new generation of highly effective, safe and targeted medicines inhumans. We think it’s time companion animals reaped the benefits of human medical progress in this field.Nexvet’s unique technology, PETisation™, ensures 100% customisation of a therapy to a new species, reducing the chances of immune challenges, and ensuring a more ‘natural’ fit between the therapy and the patient. Many chronic conditions in pets remain poorly treated by current veterinary therapies, such as pain and various inflammatory diseases– which has guided Nexvet’s focus towards these indications.To ensure we succeed in transforming animal medicine, we’ve brought together a team with an extraordinary global track record in animal and human health. We are working with leading contractors, advisors, drug development partners, academic groups, veterinarians and animal interest groups around the world to develop our pipeline to the highest standards.Senior executives and researchers from the world’s largest animal health brands are counted among our Board, management, and advisors, and together we’re building connections worldwide to make our vision a reality. | $7M / Oct 28, 2013 | ||
| Millenium Biologix Corporation operates as a biomedical company primarily in the United States and Europe. It engages in the development and commercialization of implantable medical devices and skeletal tissue regeneration products for various orthopedic uses. The company offers Skelite, a synthetic bone graft, for healing and replacement.Millenium Biologix also develops Primacoll and Peptos for the stimulation of bone tissue growth. In addition, it offers ACTES, a cell culture and tissue engineering system, which provides automated control over the biological process of tissue engineering. The company was founded in 1986 and is headquartered in Kingston, Canada. | $1.2M / Aug 18, 2006 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does BioScience Managers Limited invest in?
BioScience Managers Limited invests primarily in Health Care, Biotechnology and Medical startups, most often at Funding Round and Post-IPO Equity stage. Most of the 9 investments tracked by Shizune back companies in Australia. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact BioScience Managers Limited?
Public channels for BioScience Managers Limited include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at BioScience Managers Limited?
The team at BioScience Managers Limited includes Amanda Gillon (Investment Analyst), Matt McNamara (Managing Director) and Nora Frey (Investment Manager), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
